A Phase 3 interventional study of Lenvatinib and Pembrolizumab in Carcinoma, Hepatocellular, sponsored by Merck Sharp & Dohme LLC. Terminated at 205 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 4th largest by enrollment, is one of 13 that started in 2020, is one of 13 in phase 3, and was the 26th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 79 · Phase 3 17 · Phase 4 5
First in 2009; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 480 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 48 across the 121 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 14 finished, 11 (79%) have results posted.
Among the 14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc, this one is the 5th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 13th registered.
Merck & Co., Inc’s Carcinoma, Hepatocellular studies by the year they started, since 2002.
14 of the studies testing lenvatinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT07081633AstraZenecaDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | 2026-11-30 |
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT06524466Sun Yat-sen UniversityNeoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | 2026-12-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, from their registry updates:
Among Merck & Co., Inc’s 14 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years \[\~35 cycles\] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
Drug: Lenvatinib · Biological: Pembrolizumab · Procedure: TACE
Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (\~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
Drug: Oral Placebo · Drug: IV Placebo · Procedure: TACE
Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
Also known as: MK-7902, E7080, LENVIMA®
Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
Also known as: MK-3475, KEYTRUDA®
Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
Conducted as a background procedure of chemotherapeutic and embolic agent(s).
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 as assessed by BICR was reported.
Time frame: Up to approximately 43.5 Months
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 61.7 Months
PFS Per Modified RECIST (mRECIST) as Assessed by BICR
PFS was defined as the time from the first dose of study intervention to the first documented PD per mRECIST by BICR or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma (HCC) allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the SODs of viable target lesions, taking as reference the smallest SODs of viable target lesions recorded since the treatment started. PFS per mRECIST as assessed by BICR was reported.
Time frame: Up to approximately 61.7 Months
Objective Response Rate (ORR) Per mRECIST as Assessed by BICR
ORR was defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. The percentage of participants who experienced CR or PR per mRECIST as assessed BICR was presented.
Time frame: Up to approximately 61.7 Months
Disease Control Rate (DCR) Per mRECIST as Assessed by BICR
DCR was defined as the percentage of participants who have achieved a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per mRECIST assessed by BICR was presented.
Time frame: Up to approximately 61.7 Months
Duration of Response (DOR) Per mRECIST as Assessed by BICR
For participants who demonstrated confirmed CR or PR per mRECIST assessed by BICR, DOR was defined as the time from the first documented evidence of a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using mRECIST for all participants who experienced a confirmed CR or PR was presented.
Time frame: Up to approximately 61.7 Months
Time-To-Progression (TTP) Per mRECIST as Assessed by BICR
TTP was defined as the time from the first dose of study intervention to the first documented PD per mRECIST assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per mRECIST as assessed by BICR was presented.
Time frame: Up to approximately 61.7 Months
Number of Participants Who Experienced At Least One Adverse Event (AE)
An AE will be any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.
Time frame: Up to approximately 71.1 Months
Percentage of Participants Who Experience At Least One Serious Adverse Event (SAE)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. The number of participants with an SAE was reported.
Time frame: Up to approximately 71.1 Months
Number of Participants Who Experience At Least One Hepatic Event of Clinical Interest (ECI)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Hepatic events of clinical interest (ECIs) included any of the following events if the event was considered not due to disease progression as judged by the investigator: among participants with Baseline ALT \<2 × ULN: ALT ≥5 × ULN; among participants with Baseline ALT ≥2 × ULN: ALT \>3 × the Baseline level; ALT \>500 U/L regardless of baseline level; total bilirubin \>3.0 mg/dL; hepatic decompensation diagnosed clinically (regardless of laboratory values) including new onset clinically detectable ascites requiring intervention for \>3 days, hepatic encephalopathy, or gastrointestinal bleeding suggestive of portal hypertension. The number of participants with a hepatic AE of clinical interest was reported.
Time frame: Up to approximately 71.1 Months
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported.
Time frame: Up to approximately 71.1 Months
ORR Per RECIST 1.1 as Assessed by BICR
ORR was defined as the percentage of participants who achieve a confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ, and assessed by BICR. The percentage of participants who experienced CR or PR per RECIST 1.1 as assessed BICR was presented.
Time frame: Up to approximately 61.7 Months
DCR Per RECIST 1.1 as Assessed by BICR
DCR was defined as the percentage of participants who have achieved CR (disappearance of all target lesions), PR (at least a 30% decrease in the SOD of target lesions), or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) after ≥6 weeks (the start of the window for the first scheduled scan) per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per RECIST 1.1 assessed by BICR was presented.
Time frame: Up to approximately 61.7 Months
DOR Per RECIST 1.1 as Assessed by BICR
For participants who demonstrated confirmed CR or PR per RECIST 1.1 assessed by BICR, DOR was defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the SOD of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.
Time frame: Up to approximately 61.7 Months
TTP Per RECIST 1.1 as Assessed by BICR
TTP was defined as the time from the first dose of study intervention to the first documented PD per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per RECIST 1.1 as assessed by BICR was presented.
Time frame: Up to approximately 61.7 Months
| Milestone | Lenvatinib Plus Pembrolizumab Plus TACE | Oral Placebo Plus IV Placebo Plus TACE |
|---|---|---|
| Started | 237 | 243 |
| Treated | 237 | 241 |
| Participants ongoing | 105 | 114 |
| Completed | 0 | 0 |
| Not completed | 237 | 243 |
| Withdrew: Death | 124 | 122 |
| Withdrew: Randomized by mistake without study treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 6 |
| Withdrew: Participants ongoing | 105 | 114 |
PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 as assessed by BICR was reported.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | 14.6 (12.6 to 16.7) | 10.0 (8.1 to 12.2) |
OS was defined as the time from randomization to death due to any cause.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Overall Survival (OS) | 40.4 (34.4 to 47.0) | 40.8 (35.2 to 45.8) |
PFS was defined as the time from the first dose of study intervention to the first documented PD per mRECIST by BICR or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma (HCC) allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the SODs of viable target lesions, taking as reference the smallest SODs of viable target lesions recorded since the treatment started. PFS per mRECIST as assessed by BICR was reported.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| PFS Per Modified RECIST (mRECIST) as Assessed by BICR | 14.6 (12.5 to 17.6) | 9.8 (8.1 to 11.1) |
ORR was defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. The percentage of participants who experienced CR or PR per mRECIST as assessed BICR was presented.
| Percentage of Participants | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Objective Response Rate (ORR) Per mRECIST as Assessed by BICR | 71.3 (65.1 to 77.0) | 49.4 (42.9 to 55.8) |
DCR was defined as the percentage of participants who have achieved a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per mRECIST assessed by BICR was presented.
| Percentage of Participants | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Disease Control Rate (DCR) Per mRECIST as Assessed by BICR | 90.3 (85.8 to 93.7) | 81.9 (76.5 to 86.5) |
For participants who demonstrated confirmed CR or PR per mRECIST assessed by BICR, DOR was defined as the time from the first documented evidence of a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using mRECIST for all participants who experienced a confirmed CR or PR was presented.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Duration of Response (DOR) Per mRECIST as Assessed by BICR | 14.5 (12.5 to 16.6) | 12.5 (10.4 to 14.7) |
TTP was defined as the time from the first dose of study intervention to the first documented PD per mRECIST assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per mRECIST as assessed by BICR was presented.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Time-To-Progression (TTP) Per mRECIST as Assessed by BICR | 16.6 (14.5 to 18.9) | 10.2 (8.2 to 12.3) |
An AE will be any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. The number of participants with an SAE was reported.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Hepatic events of clinical interest (ECIs) included any of the following events if the event was considered not due to disease progression as judged by the investigator: among participants with Baseline ALT \<2 × ULN: ALT ≥5 × ULN; among participants with Baseline ALT ≥2 × ULN: ALT \>3 × the Baseline level; ALT \>500 U/L regardless of baseline level; total bilirubin \>3.0 mg/dL; hepatic decompensation diagnosed clinically (regardless of laboratory values) including new onset clinically detectable ascites requiring intervention for \>3 days, hepatic encephalopathy, or gastrointestinal bleeding suggestive of portal hypertension. The number of participants with a hepatic AE of clinical interest was reported.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported.
Results for this outcome have not been posted.
ORR was defined as the percentage of participants who achieve a confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ, and assessed by BICR. The percentage of participants who experienced CR or PR per RECIST 1.1 as assessed BICR was presented.
| Percentage of Participants | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| ORR Per RECIST 1.1 as Assessed by BICR | 48.1 (41.6 to 54.7) | 33.7 (27.8 to 40.1) |
DCR was defined as the percentage of participants who have achieved CR (disappearance of all target lesions), PR (at least a 30% decrease in the SOD of target lesions), or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) after ≥6 weeks (the start of the window for the first scheduled scan) per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per RECIST 1.1 assessed by BICR was presented.
| Percentage of participants | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| DCR Per RECIST 1.1 as Assessed by BICR | 89.9 (85.3 to 93.4) | 81.1 (75.6 to 85.8) |
For participants who demonstrated confirmed CR or PR per RECIST 1.1 assessed by BICR, DOR was defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the SOD of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| DOR Per RECIST 1.1 as Assessed by BICR | 14.3 (12.1 to 16.6) | 12.6 (9.8 to 16.9) |
TTP was defined as the time from the first dose of study intervention to the first documented PD per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per RECIST 1.1 as assessed by BICR was presented.
| Months | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| TTP Per RECIST 1.1 as Assessed by BICR | 16.6 (14.6 to 18.5) | 10.4 (8.2 to 12.5) |
Collected over Up to approximately 61.7 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib + Pembrolizumab + TACE | 126/237 (53.2%) | 122/237 (51.5%) | 234/237 (98.7%) |
| Placebo + TACE | 127/243 (52.3%) | 62/241 (25.7%) | 229/241 (95%) |
| Event | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 12/237 | 2/241 |
| DiarrhoeaGastrointestinal disorders | 8/237 | 0/241 |
| Blood bilirubin increasedInvestigations | 8/237 | 0/241 |
| AscitesGastrointestinal disorders | 7/237 | 0/241 |
| Liver abscessInfections and infestations | 3/237 | 6/241 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 5/237 | 3/241 |
| Platelet count decreasedInvestigations | 3/237 | 5/241 |
| Acute myocardial infarctionCardiac disorders | 4/237 | 0/241 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 4/237 | 1/241 |
| Cholecystitis acuteHepatobiliary disorders | 4/237 | 0/241 |
| Event | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE |
|---|---|---|
| HypertensionVascular disorders | 126/237 | 53/241 |
| ProteinuriaRenal and urinary disorders | 105/237 | 27/241 |
| Platelet count decreasedInvestigations | 96/237 | 63/241 |
| Alanine aminotransferase increasedInvestigations | 94/237 | 79/241 |
| Aspartate aminotransferase increasedInvestigations | 92/237 | 77/241 |
| Weight decreasedInvestigations | 91/237 | 17/241 |
| HypothyroidismEndocrine disorders | 84/237 | 20/241 |
| Blood bilirubin increasedInvestigations | 84/237 | 56/241 |
| Decreased appetiteMetabolism and nutrition disorders | 83/237 | 31/241 |
| DiarrhoeaGastrointestinal disorders | 76/237 | 22/241 |
The baseline analysis population consisted of all randomized participants. Participants will be analyzed in the treatment group to which they are randomized.
| Age, Continuous(Years) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| Mean | 63.8 ± 10.7 | 65.2 ± 10.4 | 64.5 ± 10.6 |
| Sex: Female, Male(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| Female | 45 | 37 | 82 |
| Male | 192 | 206 | 398 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 33 | 64 |
| Not Hispanic or Latino | 193 | 199 | 392 |
| Unknown or Not Reported | 13 | 11 | 24 |
| Race (NIH/OMB)(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 168 | 179 | 347 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 51 | 47 | 98 |
| More than one race | 7 | 7 | 14 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| ECOG= 0 | 216 | 213 | 429 |
| ECOG= 1 | 21 | 30 | 51 |
| Geographic Region(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| Asia without Japan | 135 | 137 | 272 |
| Non-Asia with Japan | 102 | 106 | 208 |
| Serum Albumin (ALBI) Grade(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| Grade 1 | 171 | 174 | 345 |
| Grade 2 | 65 | 69 | 134 |
| Missing | 1 | 0 | 1 |
| Tumor Burden Stratum per Investigator(Participants) | Lenvatinib + Pembrolizumab + TACE | Placebo + TACE | Total |
|---|---|---|---|
| ≤ 6 | 112 | 116 | 228 |
| > 6 and ≤ 12 | 120 | 117 | 237 |
| > 12 | 5 | 10 | 15 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 205 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from May 2020 to primary completion in Aug 2025, 62 months.
Results were first posted in Sep 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Pembrolizumab